RxDoctor Payments Data

Robert Taylor, DPM

Podiatrist · Portland, MENPI 1659308971

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Treace Medical Concepts, Inc. at 38.1% of the total. Reporting peaked in 2024 at $895 and has fallen 70.3% since, to $266 in 2025.

$2,683in general payments, 2019–2025

Across 56 payments — averaging $47.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$1K
  • Organogenesis Inc.$310
  • Celularity Inc.$263
  • Bone Support Inc.$221
  • Next Science LLC$173
  • Mimedx Group, Inc.$153
  • plus $541 from 12 others

What the payments were for

  • Food & beverage$2,683100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,683 in reported general payments places this provider in the 70th percentile of 20 podiatrist providers in Maine.

See all podiatrist providers in Maine

Medicare billing

Part B allowed, 2024
$186,810
Medicare patients
541
Services billed
2,377

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ammonium Lactate44$845
Ciclopirox16$487
Pregabalin14$274
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$193
Gabapentin14$44

Paid to pharmacies, not to this prescriber.

Other podiatrist in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →